Gianrico Farrugia, President and CEO at Mayo Clinic, shared a post on LinkedIn:
“Mayo Clinic researchers have contributed to the development of a simple blood test that can noninvasively profile tumor microenvironments, helping to better predict which cancer patients may benefit from immunotherapy.
Read how their findings show promise for guiding more personalized treatment options.”
Other articles featuring Gianrico Farrugia on OncoDaily.